Unlearn.AI

Unlearn.AI is developing a digital twin platform to conduct faster and smaller clinical trials on patients. The technological platform, TwinRCT, uses ML and historical data to conduct randomized trials by altering the digital twin to obtain primary and secondary outcomes of treatment effects. The historical data gathered is incorporated into the digital twin to gather demographic information, test results, and biomarkers to replicate actual patient records in the clinical trial. 

The platform covers various disease areas, including Alzheimer’s, multiple sclerosis, Parkinson’s, and ulcerative colitis. Furthermore, this platform is approved by the European Medicines Agency as a methodology for Phase II and III clinical studies. As of January 2023, it was yet to obtain a process approval from the FDA. 

The company operates a B2B business model and provides services to pharma sponsors, biotechnological companies, and academic institutions.

Key customers and partnerships

In February 2022, the company entered a multi-year collaboration with German pharma company Merch KGaA to incorporate the TwinRCT in randomized controlled trials in its immunology products. 

Funding and financials

In February 2024, the company raised USD 50 million in a Series C funding round led by Altimeter Capital. The new funds were allocated towards Unlearn's workforce, data, engineering, and long-term R&D efforts.